Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Feb. 2, 2024 /PRNewswire/ — Akebia Therapeutics^®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly-hired employees options to purchase an aggregate of 856,950 shares of Akebia’s common stock on January 31, 2024, including an option to purchase 454,950 shares to Nik Grund, Akebia’s newly hired Chief Commercial Officer, and an option to purchase 336,000 shares to Richard Malabre, Akebia’s newly hired Chief Accounting Officer. The options were granted as an inducement material to each such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Read more at prnewswire.com